Propranolol is a beta adrenergic receptor-blocking medication used to treat or prevent high blood pressure, PTSD, irregular heartbeats, tremors, angina pectoris, migraine, and anxiety. Hypertension is the leading risk factor for disability and death worldwide, according to a study published in the American Heart Association, Inc.
In 2010, the Asia and Pacific region had the highest burden of hypertension, with 439 million people affected. According to WHO, propranolol is one of the most important pharmaceutical drugs needed in a basic health system. The drug is a nonselective beta blocker that can cross the blood-brain barrier. It inhibits neurotransmitter action and improves memory consolidation.
Propranolol’s advantage made it useful for brain disorders as well, resulting in a positive impact of propranolol drug in both heart and brain disorders. The drug propranolol is being studied as a potential treatment for post-traumatic stress disorder. Propranolol was first marketed as Inderal by ICI Pharmaceutical, which is now known as AstraZeneca, in 1965.
For Critical Insights, Request for Sample@
https://www.futuremarketinsights.com/reports/sample/rep-gb-2028
Because propranolol is a non-selective beta-blocker, it has similar effects on the lungs, heart, and other areas of the body, which contributes to adverse effects such as allergic reaction, breathing problems, sudden weight gain, blood sugar changes, and so on. Alternative options for propranolol drugs and drug side effects may limit the market’s growth.
This segment includes tablets and extended-release capsules, which are more preferred and have better patient outcomes. In the propranolol drug market, hypertension accounts for a large share of the disease indication segment when compared to other disease types. Because hypertension is a chronic disease, patients may need to take medication every day for the rest of their lives.
Asia-Pacific, on the other hand, is expected to grow rapidly over the forecast period due to changing lifestyles and a growing disease population. Furthermore, various public awareness campaigns launched by medical organisations to encourage people to get regular checkups and explore available treatment options will result in a significant growth opportunity.
Inquire Before Buying Research Report@
https://www.futuremarketinsights.com/askus/rep-gb-2028
Based on of route of administration, the global propranolol drug market is segmented into the following:
- Oral administration
- Solid
- Liquid
- IV administration
Based on disease indication, the global propranolol drug market is segmented into the following:
- Hypertension
- Angina
- Migraine
- Tremors
Based on end user, the global propranolol drug market is segmented into the following:
- Hospitals
- Clinics
- Home care settings
- Ambulatory Surgical Centers
Read Related Reports:
- https://degentevakana.com/blogs/view/123347
- https://inobee.com/read-blog/123636
- https://kaalama.org/read-blog/202451
- https://blacksocially.com/read-blog/74945
About FMI
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Report: https://www.futuremarketinsights.com/reports/propranolol-drug-market
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs